Spotlight
Clinical
Video Series
News
Publication
CME/CE
Partners
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
EP: 1.C. Difficile Risk Factors and Manifestation
EP: 2.Strains of C. Difficile
EP: 3.Managing Community-Onset C. Difficile
EP: 4.Recurrent C. Difficile
EP: 5.C. Difficile: A Differential Diagnosis
EP: 6.Testing for C. Difficile Infections
EP: 7.Screening for C. Difficile
EP: 8.C. Difficile: Clinical Practice Guidelines and Treatment Options
EP: 9.C. Difficile: Updates to Clinical Practice Guidelines
EP: 10.Selecting Therapy to Treat C. Difficile
EP: 11.C. Difficile Treatment: Fidaxomicin
EP: 12.Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
Now Viewing
EP: 13.C. Difficile Treatment: Bezlotoxumab
EP: 14.Preventing/Treating C. Difficile: Unmet Needs
EP: 15.Fecal Microbiota Transplantation for C. Difficile Infections
EP: 16.Emerging Treatment Options for C. Difficile Infections
EP: 17.C. Difficile: Barriers Treating With FMT
EP: 18.Making Strides in the Management of C. Difficile
Related Videos
Related Content
